The Krka Group sold €300.9 million (4% growth) worth of products and services in the reported period, resulting in €40.2 million of net profit. The Krka Company sold €263.4 million worth of products and generated €32.8 million of net profit.
The Krka Group’s sales totalled €300.9 million, up 4% compared to the first quarter last year. Sales volume increased by more than 12%. Sales in markets outside Slovenia represent over 93% of the Group’s total sales.
Krka Company sales, which amounted to €263.4 million, were up 1% relative to the same period last year.
Krka Group sales by Region
Regions West Europe and East Europe contributed 26.6% of overall Group sales each and are thus Krka’s largest sales regions.
Three-month sales in West Europe totalled €80.0 million and in the majority of markets in the Region sales volume was up. Sales value is down 3% compared to the same period last year. Sales in East Europe totalled €80.1 million, a 2% decrease to the same period last year. Product sales in Region Central Europe, which represents a 24.3% share in overall Group sales, amounted to €73.0 million, which is up 7%. Sales in Region South-East Europe represent 12.5% of Group sales, as they totalled €37.7 million. This is an increase by 23%, or €7.1 million, relative to the same period last year, and constitutes the highest absolute sales growth among all Krka’s sales regions. Sales in the domestic market totalled €20.2 million, which is an increase by 5% and represents 6.7% of overall Group sales. In Region Overseas Markets sales totalled €9.9 million (3.3% of overall Group sales), constituting the highest relative sales growth among all regions, of 33%.
Krka Group sales by product and service group
The Group sold €243.9 million worth of prescription pharmaceuticals in the reported period, up 0.3% compared to the first quarter last year. Prescription pharmaceuticals represent 81% of Krka Group sales. Their sales increased in the regions Overseas Markets (by 28%), South-East Europe (by 25%), Central Europe (by 5%) and East Europe (by 1%).
The ten leading prescription pharmaceuticals in terms of sales are Atoris (atorvastatin), Lorista (losartan), Nolpaza (pantoprazole), Prenessa (perindopril), Emanera (esomeprazole), Enap (enalapril), Valsacor (valsartan), Roswera (rosuvastatin), Zyllt (clopidogrel) and Dulsevia (duloxetine). Products are marketed under different brand names in individual markets.
Non-prescription product sales were up 1% compared to the same period last year, to €27.4 million, which represents 9.1% of Krka Group sales. The sales of animal health products were up 85% to €21.8 million, which is 7.2% of overall Group sales. Health resort and tourist services totalled €7.2 million in revenues, an 11% year-on-year increase (2.4% of total sales).
Research and development
In the first quarter of 2016 Krka obtained marketing authorisations for three new products in three dosage forms and four strengths, and acquired 69 new marketing authorisations in different markets.
In the first quarter of 2016 the Krka Group allocated €26.2 million to investments, of which the controlling company invested €18.5 million and subsidiaries €7.7 million. Investments are primarily increasing and modernising their production capacities, and research and development capacities.
In the first quarter of 2016 the number of Krka Group employees increased by 144, or 1.4%, so that at the end of March there were 10,708. Krka’s subsidiaries and representation offices outside Slovenia employ more than 54% of the Group’s employees, and almost 56% of the entire Krka team have at least a university level degree.
More information in press release.